What the boxed warning says, in plain words
The boxed warning on semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) is about one specific cancer: medullary thyroid carcinoma, or MTC. It does not say these medicines cause thyroid cancer in people. It says they caused thyroid tumors in rodents, and that nobody yet knows whether that finding applies to humans.
The Wegovy label puts it this way: in mice and rats, semaglutide caused a dose-dependent and duration-dependent increase in thyroid C-cell tumors after lifetime exposure at clinically relevant levels. The human relevance of that finding has not been determined. The label also notes postmarketing reports of MTC in people taking liraglutide, an older drug in the same class, and says those reports are not enough to establish or rule out a causal link.
Why rodent tumors led to the strongest kind of warning
A boxed warning is the FDA’s most prominent caution, and it is used when a risk is serious enough to shape who should take a drug. C-cells, the cells MTC grows from, make the hormone calcitonin and carry GLP-1 receptors. In rodents, stimulating those receptors for a lifetime drove C-cell growth.
Whether human C-cells respond the same way is the open question. Because MTC is rare and slow to develop, it takes very large groups of people followed for years to answer it, which is why the warning has stayed in place while the human data build up.
What human studies have found since
Two large studies are the ones most often cited, and they point in different directions.
| Study | Who was studied | Main finding |
|---|---|---|
| French case-control study, Diabetes Care, 2023 | 2,562 people with thyroid cancer and 45,184 matched controls, all with type 2 diabetes | 1 to 3 years of GLP-1 use linked to higher risk of all thyroid cancer (HR 1.58) and MTC (HR 1.78) |
| Scandinavian cohort, BMJ, 2024 | 145,410 GLP-1 users compared with 291,667 users of another diabetes drug class | No meaningful increase in thyroid cancer (HR 0.93); MTC estimate uncertain (HR 1.19, wide range) |
The French study used national insurance records and found the higher risk mainly after one to three years of use. One concern with that design is detection: people starting a new diabetes medicine may get more neck imaging and blood work, which can uncover small thyroid cancers that were already there.
The Scandinavian cohort compared new users of GLP-1 drugs with new users of DPP-4 inhibitors across Denmark, Norway and Sweden. Thyroid cancer occurred at 1.33 cases per 10,000 person-years in the GLP-1 group and 1.46 in the comparison group. The authors concluded the data were consistent with no more than a 31% relative increase, but the average follow-up was 3.9 years and MTC cases were too few for a firm answer.
Those rates also show how uncommon the outcome is in absolute terms. If 10,000 people took either type of medicine for a year, roughly one or two would be diagnosed with any kind of thyroid cancer, and MTC would be a small fraction of that.
Put together, the human evidence does not show a clear increase in thyroid cancer, and it cannot rule out a small one for MTC. That uncertainty is exactly what the warning describes.
Why MTC or MEN 2 history rules these medicines out
Both drugs are contraindicated in anyone with a personal or family history of MTC or with multiple endocrine neoplasia type 2 (MEN 2). These are the people for whom even a small added risk would matter most.
MEN 2 is an inherited condition caused by changes in the RET gene. MedlinePlus Genetics estimates it affects about 1 in 35,000 people, and its most common feature is medullary thyroid carcinoma. Some families carry a form where MTC is the only feature, so a relative’s “thyroid cancer” history is worth clarifying: ask which type it was.
It is worth asking relatives directly before your first visit. A history of the more common papillary type of thyroid cancer is a different situation, and your provider will weigh it separately.
Symptoms to report while on treatment
MedlinePlus lists the signs to call about right away: a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. None of these means you have cancer, and most neck lumps are benign, but each deserves an exam rather than waiting for your next check-in.
If shortness of breath is sudden or severe, or comes with chest pain, that is not a clinic call. Call 911 or go to the nearest emergency room.
What this means for men deciding on treatment
For most men without a relevant history, the thyroid warning is one item in a broader risk and benefit discussion that also covers stomach side effects, gallbladder and pancreas risks, and the health effects of the excess weight itself. Men with type 2 diabetes, obesity or a history of thyroid nodules often ask whether they are at extra risk. Those factors do not appear as contraindications on the label, but they are worth raising, because they can change how closely your provider watches your neck exam and symptoms over time.
Our page on who should not take semaglutide lists the other reasons to pass, and the shorter semaglutide thyroid cancer answer is a quick reference.
It also helps to separate this warning from the wider myths about these medicines. Our GLP-1 myths article checks the claims about muscle, lifestyle and lifelong use against the trial data.
How Ultimate Male screens before starting
Before semaglutide or tirzepatide is on the table, your provider takes a full personal and family history, including the type of any thyroid cancer in relatives, and reviews your pre-treatment blood work. If anything points to MTC or MEN 2, a GLP-1 is off the list and we discuss other parts of a medical weight loss plan instead.
If you are already on one of these medicines from another source and have questions about the warning, bring the medicine name, dose and your family history to a free 10-minute call. We will tell you plainly whether a consultation makes sense.
